Overview
The purpose of this study is to investigate if lymphocyte markers predict response to rituximab among patients with idiopathic nephrotic syndrome
Eligibility
Inclusion Criteria:
- Age 1-18 years old at the time of diagnosis of nephrotic syndrome
- Steroid-dependent (SDNS) or steroid-resistant nephrotic syndrome (SDNS)
Exclusion Criteria:
- eGFR <60 ml/min per 1.73m2
- infantile onset of nephrotic syndrome
- nephrotic syndrome secondary to chronic infections such as hepatitis B, hepatitis C or human immunodeficiency virus, systemic lupus erythematosus, Henoch-Schönlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis or membranous nephropathy
- current or previous therapy for tuberculosis
- presence of mutations in WT1, NPHS1, NPHS2 and TRPC6.
